reports
EQS-News: OCEANSIX FUTURE PATHS FAIT L’ACQUISITION D’ORIGINAL REPACK O...
EQS-News: oceansix future paths Ltd. / Mot-clé(s) : Autres OCEANSIX FUTURE PATHS FAIT L’ACQUISITION D’ORIGINAL REPACK OY 16.05.2024 / 10:00 CET/CEST Tel Aviv, Israël (15 mai 2024) – oceansix Future Paths Ltd. (« Oceansix » ou la « société »), une société leader en matière de solutions technologiques avancées de recyclage et de fabrication, présent à la Bourse de croissance TSX à Toronto (TSXV : CUSIP 001194828, OSIX), à New York (OTCQB : AKMYF) et à la Bourse de Francfort (WKN : A3EFB0, ISIN : IL0011948283, 5FC0), a le plaisir d’annoncer qu’elle a conclu aujourd’hui un accor...
EQS-News: Sartorius to advance drug discovery and manufacturing with A...
EQS-News: SARTORIUS AG / Key word(s): Alliance Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA (news with additional features) 16.05.2024 / 09:54 CET/CEST The issuer is solely responsible for the content of this announcement. Göttingen, Germany, May 16, 2024 Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, and pre...
Deceuninck NV: 1 director
A director at Deceuninck NV sold 500,000 shares at 2.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Johanna Jourdain
Elior : Encouraging H1 2024 results driving an upgrade to FY guidance ...
>H1 2023-24 results above expectations, with a significant beat on EBITA - Elior reported H1 2023-24 results (Oct. 2023 to March 2024) that beat expectations. Sales were € 3,123m, in line with the consensus at € 3,109m and up 26% on a reported basis. Organic growth was 5.9%, a shade above the consensus at 5.7% (ODDO BHF 6.5%e). We note an improvement in the retention rate to 92.3% (vs 91.3% in H1 2022-23), which remains impacted by voluntary contract exits (-1.3%). W...
- Aurelien Sivignon
PulluP Entertainment : Lancement surprise d’une AK pouvant aller jusqu...
>AK jusqu’à 23 M€ avec suppression du DPS / décote de 3% - PulluP a annoncé cette nuit le lancement d’une AK de 17.5 M€ (i.e. 1.5m d’actions nouvelles soit 23% du K dilué) pouvant être porté jusqu’à 23 M€ en cas d’exercice intégral de la clause d’extension et de l’option de surallocation (i.e. 2m d’actions nouvelles soit 30% du K dilué).Le prix de souscription est 11.3 € par action traduisant une décote de 3% sur le dernier cours. Le DPS est supprimé avec un dél...
Europe’s Chemical Firms Seek Catalyst for Competitiveness
LONDON--(BUSINESS WIRE)-- A somewhat diluted European chemical industry is hoping that digital technology will provide the formula it needs to regain some of its strength in the global market, according to a new research report published today by Information Services Group () (Nasdaq: ), a leading global technology research and advisory firm. The 2024 ISG Provider Lens™ Chemical Industry Services and Solutions report for Europe finds that for a chemical industry plagued by a potent mix of environmental concerns, diminished demand and escalating costs, technology-driven innovation and digital...
Share Buyback Transaction Details May 9 – May 15, 2024
Share Buyback Transaction Details May 9 – May 15, 2024 PRESS RELEASE Share Buyback Transaction Details May 9 – May 15, 2024 Alphen aan den Rijn - May 16, 2024 - Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 148,380 of its own ordinary shares in the period from May 9, 2024, up to and including May 15, 2024, for €21.7 million and at an average share price of €146.27. These repurchases are part of the share buyback program announced on February 21, ...
Manhattan, pionnier sur l’utilisation de l’IA Générative pour la Suppl...
PARIS--(BUSINESS WIRE)-- (NASDAQ : MANH) annonce aujourd’hui la sortie conjointe de Manhattan Active® Maven, nouvelle solution de service client basée sur l’intelligence artificielle générative (GenAI), et de Manhattan Assist, qui vient enrichir toutes les solutions Manhattan Active avec des fonctionnalités GenAI. Avec l’intégration de cette technologie de dernière génération, Manhattan fait entrer les interactions client et l’usage de ses solutions dans une nouvelle ère. Manhattan Active Maven utilise la puissance de la technologie GenAI pour améliorer l’expérience client et réduire les co...
Manhattan Pioneers Use of GenAI in Supply Chain Commerce
LONDON--(BUSINESS WIRE)-- (NASDAQ: MANH) today announced Manhattan Active® Maven, a specialized Generative Artificial Intelligence (GenAI) solution built for customer service, along with Manhattan Assist, which adds cutting-edge GenAI capabilities to all Manhattan Active solutions. The company is applying this state-of-the-art technology to revolutionize consumer interactions, as well as enhancing how Manhattan's customers engage with their solutions. The new Manhattan Active Maven harnesses the power of GenAI technology to elevate customer experience while simultaneously reducing operation...
Novavax Inc: 1 director
A director at Novavax Inc sold/sold after exercising options 47,312 shares at 13.900USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Verve Therapeutics Inc: 1 director
A director at Verve Therapeutics Inc bought 76,000 shares at 6.260USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Netlink Solutions (India) Ltd: 1 director
A director at Netlink Solutions (India) Ltd sold 23,830 shares at 171.000INR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
- Cor Kluis
KBC : Q1 results marginally better vs consensus, NII going well
>Conclusion: Q1 results marginally better vs consensus - The results were marginally better than expected with a marginally better NII than consensus and marginally better cost (for us it was in line. The Solvency was also in line. We heard that some analyst had some cautious view in NII (which was better than consensus) and impairments (which was well better than consensus) before the figures so this might be some release for these. We keep our Outperform recommendat...
- Alfonso Mariategui
SIEMENS: RDOS. 2T’24 (ANÁLISIS BANCO SABADELL)
Rdos. 2T'24 vs 2T'23: Ventas: 19.162 M euros (-1,3% vs 0,0% BS(e) y -0,7% consenso); EBITDA: 2.513 M euros (-2,5% vs +8,0% BS(e) y +3,9% consenso); Rdos. 1S'24 vs 1S'23: Ventas: 37.574 M euros (+0% vs +0,9% BS(e) y +0,6% consenso); EBITDA: 5.236 M euros (+0,1% vs +5,3% BS(e) y +3,2% consenso).
Thule Group AB: 1 director
A director at Thule Group AB sold 40,000 shares at 321.900SEK and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Stephane Beyazian
Freenet AG : Q1 2024: maintaining TV momentum but costs rising
>Q1 2024: in line with the consensus - Q1 2024 revenues were stable at € 639m (consensus € 642m), driven by the media/TV business (+16%) which offset the decline in mobile (-3%) due to sharply lower handset sales from Gravis stores (no EBITDA impact given virtually zero margin). EBITDA dropped by 3% to € 124m (cons. € 125m), due to TV marketing spend and personnel expense (+12%). Q1 2024 FCF rose by 9% to € 71m (cons. € 69m) solely as a result of calendar effects on ...
Seagate Technology Holdings Plc: 1 director
A director at Seagate Technology Holdings Plc sold 9,703 shares at 95.000USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
MRC Global Inc: 4 directors
Four Directors at MRC Global Inc sold/sold after exercising options 229,045 shares at between 13.601USD and 13.780USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.